Inflammometry: the current state of play

Ian D Pavord,¹ Peter G Gibson²

It is now 20 years since the late Freddy Hargreave and colleagues developed a valid, safe and feasible technique to assess airway inflammation using induced sputum.^{1–3} At around the same time Kjell Alving and colleagues reported that the concentration of exhaled nitric oxide (FE_{NO}) is raised in patients with asthma.⁴ There has since been huge research interest in these techniques over the last 20 years and both are increasingly used in clinical practice. This has led to a number of key and often unexpected observations which have changed the way we think about inflammatory airway disease. First, the presence of eosinophilic airway inflammation, regarded as a *sine qua non* of asthma, is neither closely related to the pattern nor to the severity of airway dysfunction or symptoms.^{5–7} Second, the presence of eosinophilic airway inflammation is more closely associated with a positive response to corticosteroids than other more traditional clinical measures, irrespective of the pattern of disease it occurs in.^{7–10} Thus, if the clinical question is should a patient with symptoms suggesting airway disease receive corticosteroid treatment (and it often is), then the identification of eosinophilic airway inflammation would be a better basis for making this decision than categorising the patient or applying other tests. Third, a raised FE_{NO} level appears to be just as good an indicator of a positive response to corticosteroids in a heterogeneous population of patients with symptoms suggesting airway disease.^{11–14}

The close link between these markers and corticosteroid responsiveness together with the development of inexpensive nitric oxide monitors has led us to recommend a new approach to the management of airways disease with the emphasis more on assessing airway

inflammation and likely steroid responsiveness than on diagnostic labelling.¹⁵ This approach, often known as inflammationometry, could be used to identify potentially corticosteroid disease and guide the initiation of treatment or to titrate treatment. The latter approach has been assessed in a meta-analysis¹⁶ and a clinical trial¹⁷ published in this edition of *Thorax*.

Petsky *et al*¹⁶ combined two Cochrane reviews assessing the efficacy of sputum eosinophil guided asthma management in three adult studies including a total of 246 adults with mainly moderate to severe asthma and FE_{NO} guided management in six studies including 786 children and 267 adults with milder asthma. Their analysis was compromised by differences in management algorithms, outcome measures and definitions of key outcomes but even so the sputum studies all showed a clear and consistent reduction in asthma attacks when management was guided by the sputum eosinophil count. What then are we to make of the study by Fleming *et al*¹⁷ which found no evidence of improved outcome in children with severe asthma randomised to sputum guided management?

The discrepant finding is unlikely to be due to differences in the management algorithm, which was very similar to that successfully applied by Green *et al*.¹⁸ A difference in the success rate of sputum induction is also unlikely to have been responsible but there was a suggestion that more frequent assessments of airway inflammation might have made a difference in favour of the sputum guided management. A retrospective analysis by Haldar *et al*¹⁹ suggested that most of the benefit of sputum guided management occurred in patients who had discordant symptoms and eosinophilic airway inflammation, a pattern that is particularly common in patients with severe non-atopic, adult onset asthma. The key difference in the way treatment was applied in sputum guided management was that regular oral steroids were initiated early in patients recognised to have eosinophilic airway inflammation whether this was associated with symptoms or not. Could it be that these discordant phenotypes are less prevalent or are less consistently

defined in children with severe asthma? These possibilities cannot be discounted but an alternative, and in our view a more likely explanation, is that the sputum management algorithm failed because it was not applied correctly on a significant number of occasions. It is notable that eosinophilic airway inflammation was not controlled in many of the patients randomised to sputum guided management, in marked contrast to the findings of Green *et al*.¹⁸ This may be because of a reluctance to step up to regular systemic corticosteroids, a treatment that might have had a large effect on inflammation and risk of asthma attacks. While the reluctance to make this big step in paediatric practice is readily understandable, our view is that this brave study of an important group of patients failed because the protocol was not followed, not because it was incorrect.

Petsky *et al*¹⁶ conclude that the technical expertise required to perform sputum induction and analysis is a significant barrier to its use in routine clinical practice. In this respect FE_{NO} has significant advantages as relatively inexpensive monitors are available, the technique is simple to perform and an immediate result is available. However, the outcomes of studies using FE_{NO} to titrate asthma treatment have been variable and the meta-analysis showed no overall improvement in outcome in adults or children. Interpretation of the findings is not straightforward as many of the studies were underpowered to properly evaluate the primary outcome and FE_{NO} cut points used for up and down-titration of steroids were inconsistent and often sub-optimal.²⁰ Furthermore, the largest study²¹ evaluated FE_{NO} as an adjunct to traditional symptom guided management and, illogically, used symptom control as the primary outcome, when all the evidence suggests it would work better as an alternative to symptom guided management against outcomes more closely linked to airway inflammation such as the number of asthma attacks. Most importantly, the studies have largely evaluated patients with mild to moderate asthma and influenced decisions about treatment across a range of treatment doses and against outcomes where the dose-response relationship is flat.²⁰

We are concerned that the full potential of FE_{NO} has not been explored and suggest that further studies evaluating the use of FE_{NO} as an alternative to traditional management are required. One such study, published since the meta-analysis, has shown clear evidence of improved outcome in both mother and new born in

¹Institute for Lung Health, Glenfield Hospital, Leicester, UK; ²Department of Respiratory and Sleep Medicine, Centre for Asthma and Respiratory Diseases, Hunter Medical Research Institute at John Hunter Hospital, University of Newcastle, Newcastle, Australia

Correspondence to Professor Ian D Pavord, Consultant Physician and Honorary Professor of Medicine, Institute for Lung Health, Glenfield Hospital, Leicester LE3 9QP, UK; ian.pavord@uhl-tr.nhs.uk

pregnant women whose asthma was managed by reference to FE_{NO} .²² Future studies need to clearly define the population who would most benefit from inflammometry. We suggest that there are two critical decision points with corticosteroid therapy in airways disease where the additional information provided by an objective marker of airway inflammation might be particularly valuable and where the potential benefits of appropriately applied treatment might be most marked: the decision to initiate what will often be life-long treatment; and the decision to step up therapy to high dose inhaled therapy or regular oral prednisolone in patients with more severe, complex airway disease. Perhaps future trials should focus on patients at these management points.

Competing interests None.

Provenance and peer review Commissioned; internally peer reviewed.

Thorax 2012;**67**:191–192.
doi:10.1136/thoraxjnl-2012-201712

REFERENCES

1. **Pavord ID**, Pizzichini MM, Pizzichini E, *et al*. The use of induced sputum to investigate airway inflammation. *Thorax* 1997;**52**:498–501.
2. **Pizzichini E**, Pizzichini MM, Efthimiadis A, *et al*. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. *Am J Respir Crit Care Med* 1996;**154**:308–17.
3. **Pin I**, Gibson PG, Kolendowicz R, *et al*. Use of induced sputum cell counts to investigate airway inflammation in asthma. *Thorax* 1992;**47**:25–9.
4. **Alving K**, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. *Eur Respir J* 1993;**6**:1368–70.
5. **Gibson PG**, Dolovich J, Denburg J, *et al*. Chronic cough: eosinophilic bronchitis without asthma. *Lancet* 1989;**1**:1346–8.
6. **Brightling CE**, Ward R, Goh KL, *et al*. Eosinophilic bronchitis is an important cause of chronic cough. *Am J Respir Crit Care Med* 1999;**160**:406–10.
7. **Brightling CE**, Monteiro W, Ward R, *et al*. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. *Lancet* 2000;**356**:1480–5.
8. **Brightling CE**, Ward R, Wardlaw AJ, *et al*. Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis. *Eur Respir J* 2000;**15**:682–6.
9. **Pavord ID**, Brightling CE, Woltmann G, *et al*. Non-eosinophilic corticosteroid unresponsive asthma. *Lancet* 1999;**353**:2213–14.
10. **Pizzichini E**, Pizzichini MM, Gibson P, *et al*. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. *Am J Respir Crit Care Med* 1998;**158**:1511–17.
11. **Payne DN**, Adcock IM, Wilson NM, *et al*. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. *Am J Respir Crit Care Med* 2001;**164**:1376–81.
12. **Taylor DR**, Pijnenburg MW, Smith AD, *et al*. Exhaled nitric oxide measurements: clinical application and interpretation. *Thorax* 2006;**61**:817–27.
13. **Smith AD**, Cowan JO, Brassett KP, *et al*. Exhaled nitric oxide: a predictor of steroid response. *Am J Respir Crit Care Med* 2005;**172**:453–9.
14. **Berry M**, Morgan A, Shaw DE, *et al*. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. *Thorax* 2007;**62**:1043–9.
15. **Pavord ID**, Shaw DE, Gibson PG, *et al*. Inflammometry to assess airway diseases. *Lancet* 2008;**372**:1017–19.
16. **Petsky HL**, Cates CJ, Lasserson TJ, *et al*. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). *Thorax* 2012;**67**:199–208.
17. **Fleming L**, Wilson N, Regamey N, *et al*. Use of sputum eosinophil counts to guide management in children with severe asthma. *Thorax* 2012;**67**:193–8.
18. **Green RH**, Brightling CE, McKenna S, *et al*. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. *Lancet* 2002;**360**:1715–21.
19. **Haldar P**, Pavord ID, Shaw DE, *et al*. Cluster analysis and clinical asthma phenotypes. *Am J Respir Crit Care Med* 2008;**178**:218–24.
20. **Gibson PG**. Using fractional exhaled nitric oxide to guide asthma therapy: design and methodological issues for ASThma Treatment ALgorithm studies. *Clin Exp Allergy* 2009;**39**:478–90.
21. **Szeffler SJ**, Mitchell H, Sorkness CA, *et al*. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. *Lancet* 2008;**372**:1065–72.
22. **Powell H**, Murphy VE, Taylor DR, *et al*. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. *Lancet* 2011;**378**:983–90.